10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification - a nationwide population-based study.

ABSTRACT:

Background

Treatments for inflammatory bowel diseases (IBD) have evolved in the era of biologics. However, the real-world data on their usage patterns and sequencing are still limited.

Objectives

We aimed to investigate treatment persistence and dose intensification of first- and second-line biologics in patients with IBD.

Design

In this retrospective, cohort study using nationwide claims data, 13,087 patients with IBD initiating biologic therapy between 2010 and 2020 were identified.

Methods

Treatment persistence and dose intensification during the first 2 years and switching patterns of biologics were analysed while identifying predictors of non-persistence.

Results

As a first-line treatment of Crohn's disease (CD), ustekinumab had a lower risk for non

SUBMITTER: Koo HM 

PROVIDER: S-EPMC10541745 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature